AT108 / Asgard Therapeutics - LARVOL DELTA

A cancer immunotherapy modality based on dendritic cell reprogramming in vivo (ESGCT 2024) - "Finally, CR mice treated with Ad-PIB mounted long-term immune memory, remained tumor-free for 160 days and were protected against local and metastatic colonization after subcutaneous and intravenous re-challenges. Together, our study paves the way for the first-in-human trials and provide preclinical proof-of-concept for AT-108 as an off-the-shelf, personalized cancer immunotherapy based on in situ cDC1 reprogramming."

IO biomarker • Preclinical • Oncology • BATF3 • CD40 • CD8 • IRF8

AT-108, an adenoviral vector based therapy for in situ cancer to dendritic cell reprogramming, leads to durable antitumor activity as a single agent and in combination with immune checkpoint blockade [WITHDRAWN] (ESMO 2025) - No abstract available

Checkpoint block • Checkpoint inhibition • Combination therapy • Viral vector • Oncology

Asgard Therapeutics' study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108 (PRNewswire) - "Novel data shows that AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into an immunogenic cell fate, which mounts strong anti-tumor, antigen-specific responses and durable tumor shrinkage even upon metastatic rechallenge....The study entitled, In vivo dendritic cell reprogramming for cancer immunotherapy, also shows the systematic selection of an optimal delivery system for expression of key reprogramming factors in the tumor, which led to the nomination of Asgard's lead program."

Preclinical • Oncology • Solid Tumor